TOLREMO therapeutics’ Post

🔬 Join Corina Dutcus, MD, SVP at Eisai, in a video interview discussing the phase 3 CLEAR study. Explore how lenvatinib + pembrolizumab transform advanced ccRCC treatment. Watch here: [video]https://buff.ly/3u0FV4o Eisai US ESMO - European Society for Medical Oncology

Discover more from #ASCO24! 🌟 Dr Jia (Jenny) Liu shared insights with Video Journal of Oncology (VJOncology) on Starpharma’s promising Phase 1/2 clinical trial of DEP SN38 (DEP irinotecan). The trial results, highlighted during an oral podium presentation at the 2024 ASCO Annual Meeting, showed promising anti-cancer efficacy and tolerability in very late-stage patients who were heavily pre-treated. Watch it on VJ Oncology. 📺 #CancerResearch #ClinicalTrials #Oncology #Starpharma

NEW from #ASCO2024 | Enhancing delivery of #chemotherapies with dendrimer nanoparticles 🎥 🇺🇸 Jia (Jenny) Liu, MD, PhD, St Vincent’s Hospital, comments on how #dendrimernanoparticles can improve the delivery of #chemotherapy to patients The size of the #nanoparticle can reduce off target #toxicity and prevent the drug being metabolized in the liver, reducing the severity of adverse events in patients 🔦 Learn more 👉 https://lnkd.in/e3uf7UzH #VJOncology #Oncologynews American Society of Clinical Oncology (ASCO)

🌟 Mark your calendars for Friday, December 1st and join Caidya virtually to uncover the latest strides in Adoptive Cell Therapy trial design and clinical development. This exclusive webinar brings together experts from the forefront of oncology research, offering unique perspectives from principal investigators and clinical research organizations. 🔗 Register here: https://buff.ly/46klYTs #CancerResearch #ClinicalResearch #CRO #OncologyResearch #OncologyTrials

Join us for our upcoming webinar with Xtalks on the latest advancements in adoptive cell therapy in oncology trial design and clinical development! Discover groundbreaking insights from industry experts as they discuss key considerations for clinical development and site selection in adoptive cell therapy trials. Learn about the expansion of cell therapy from hematologic malignancies to solid tumors and the patient considerations needed to optimize protocols. Featured Speakers: Sharon Moore, MD, MBA, MPH, Chief Medical Officer, Caidya; Dr. Neeta Somaiah, Associate Professor and Deputy Chair of Sarcoma Medical Oncology, MD Anderson Cancer Center; and Gaurav Sharma, Chief Development Officer, Caidya. Don't miss out on this unique opportunity to gain insights into the future of adoptive cell therapy! Register now: Adoptive Cell Therapy in Oncology: Key Considerations and Developments - Xtalks #AdoptiveCellTherapy #OncologyTrials #ClinicalDevelopment #Webinar

What are the five greatest challenges and unmet needs in oncology clinical research? Find out what they are and how Worldwide solves these obstacles in our recent report: https://bit.ly/3WxOcay

What are the five greatest challenges and unmet needs in oncology clinical research? Find out what they are and how Worldwide solves these obstacles in our recent report: https://bit.ly/3SjfKPN

#HER2DX and its impact on therapeutic #decisionmaking   Understanding its credibility, and clinical relevance is crucial for optimizing treatment strategies and enhancing patient outcomes in the context of #HER2+ #breastcancer in Clinical and Translational Oncology Read it here 👉🏻https://ow.ly/YbVo50RnSp6

OIS powered by MOSAIQ is a product of Elekta, designed to elevate patient care in the field of oncology. It is a result of decades of innovation and is designed to significantly reduce workflow complexity and enhance overall efficiency, accuracy, consistency, and performance. Learn more⬇️

OIS powered by MOSAIQ is a product of Elekta, designed to elevate patient care in the field of oncology. It is a result of decades of innovation and is designed to significantly reduce workflow complexity and enhance overall efficiency, accuracy, consistency, and performance. Learn more⬇️